148 related articles for article (PubMed ID: 30119142)
1. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma.
Zheng X; Wang W; Zhang Y; Ma Y; Zhao H; Hu P; Jiang J
Biomed Chromatogr; 2018 Dec; 32(12):e4365. PubMed ID: 30119142
[TBL] [Abstract][Full Text] [Related]
2. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
[TBL] [Abstract][Full Text] [Related]
3. Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients.
Wang W; Zheng X; Wang H; Wang L; Jiang J; Hu P
J Pharm Biomed Anal; 2017 May; 139():205-214. PubMed ID: 28285073
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.
Rood JJM; van Bussel MTJ; Schellens JHM; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1031():80-85. PubMed ID: 27469903
[TBL] [Abstract][Full Text] [Related]
5. Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.
van Veelen A; van Geel R; de Beer Y; Dingemans AM; Stolk L; Ter Heine R; de Vries F; Croes S
Biomed Chromatogr; 2020 Apr; 34(4):e4771. PubMed ID: 31808583
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC-MS/MS in Human Plasma: Application in NSCLC Patients.
Liu Y; Lin Z; Luo W; Pei X; She Z; Sha Z; Guan Y; Ming D; Liang J
J Chromatogr Sci; 2024 Apr; 62(4):339-346. PubMed ID: 37070405
[TBL] [Abstract][Full Text] [Related]
8. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
[TBL] [Abstract][Full Text] [Related]
9. Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study.
Cui X; Wang S; Gao H; Li B; Shi Y; Guo H; Song T; Zheng X
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122488. PubMed ID: 33360679
[TBL] [Abstract][Full Text] [Related]
10. An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats.
Dong ST; Li Y; Yang HT; Wu Y; Li YJ; Ding CY; Meng L; Dong ZJ; Zhang Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30404182
[TBL] [Abstract][Full Text] [Related]
11. An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients.
Cui C; Hu P; Jiang J; Kong F; Luo H; Zhao Q
J Pharm Biomed Anal; 2018 May; 153():1-8. PubMed ID: 29455091
[TBL] [Abstract][Full Text] [Related]
12. An LC-MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study.
Wang L; Zheng X; Wang W; Hu P; Jiang J
J Pharm Biomed Anal; 2017 Jul; 141():9-18. PubMed ID: 28414972
[TBL] [Abstract][Full Text] [Related]
13. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.
Rood JJM; van Haren MJ; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2020 Jan; 177():112871. PubMed ID: 31539712
[TBL] [Abstract][Full Text] [Related]
14. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a UPLC-MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study.
Wang Z; Ye W; Qin Y; You H; Zhang S; Fan F; Wang Y; Zheng L
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122475. PubMed ID: 33370688
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Rapid and Sensitive LC-MS/MS Method for the Pharmacokinetic Study of Osimertinib in Rats.
Xiong S; Deng Z; Sun P; Mu Y; Xue M
J AOAC Int; 2017 Nov; 100(6):1771-1775. PubMed ID: 28534470
[TBL] [Abstract][Full Text] [Related]
18. An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study.
Gu EM; Huang C; Liang B; Yuan L; Lan T; Hu G; Zhou H
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Aug; 997():70-4. PubMed ID: 26094207
[TBL] [Abstract][Full Text] [Related]
19. UPLC-MS/MS assay for the simultaneous determination of pyrotinib and its oxidative metabolite in rat plasma: Application to a pharmacokinetic study.
Chai H; Ai Y; Cao Z
Biomed Chromatogr; 2021 Dec; 35(12):e5221. PubMed ID: 34331710
[TBL] [Abstract][Full Text] [Related]
20. Determination of kurarinone in rat plasma by UPLC-MS/MS.
Zhang WM; Li RF; Qiu JF; Zhang ZY; Wang HB; Bian L; Lei JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Apr; 986-987():31-4. PubMed ID: 25703950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
